Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.
Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, Weber SF, Krisam J, Baumann L, Stermann J, Merle U, Weigand MA, Nusshag C, Bullinger L, Schrezenmeier JF, Bornhäuser M, Alakel N, Witzke O, Wolf T, Vehreschild MJGT, Schmiedel S, Addo MM, Herth F, Kreuter M, Tepasse PR, Hertenstein B, Hänel M, Morgner A, Kiehl M, Hopfer O, Wattad MA, Schimanski CC, Celik C, Pohle T, Ruhe M, Kern WV, Schmitt A, Lorenz HM, Souto-Carneiro M, Gaeddert M, Halama N, Meuer S, Kräusslich HG, Müller B, Schnitzler P, Parthé S, Bartenschlager R, Gronkowski M, Klemmer J, Schmitt M, Dreger P, Kriegsmann K, Schlenk RF, Müller-Tidow C. Denkinger CM, et al. Among authors: tepasse pr. Nat Cancer. 2023 Jan;4(1):96-107. doi: 10.1038/s43018-022-00503-w. Epub 2022 Dec 29. Nat Cancer. 2023. PMID: 36581734 Free PMC article. Clinical Trial.
Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19.
Dugas M, Grote-Westrick T, Merle U, Fontenay M, Kremer AE, Hanses F, Vollenberg R, Lorentzen E, Tiwari-Heckler S, Duchemin J, Ellouze S, Vetter M, Fürst J, Schuster P, Brix T, Denkinger CM, Müller-Tidow C, Schmidt H, Tepasse PR, Kühn J. Dugas M, et al. Among authors: tepasse pr. J Clin Virol. 2021 Jun;139:104847. doi: 10.1016/j.jcv.2021.104847. Epub 2021 Apr 24. J Clin Virol. 2021. PMID: 33965698 Free PMC article.
Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
Boeckel GR, Hölscher SD, Bürger C, Jacob T, Krekeler C, Shumilov E, Reicherts C, Bleckmann A, Lenz G, Vollenberg R, Tepasse PR. Boeckel GR, et al. Among authors: tepasse pr. Curr Oncol. 2022 Mar 26;29(4):2312-2325. doi: 10.3390/curroncol29040188. Curr Oncol. 2022. PMID: 35448162 Free PMC article.
Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis.
Shumilov E, Aperdannier L, Schmidt N, Szuszies C, Neesse A, Hoffknecht P, Khandanpour C, Mikesch JH, Stelljes M, Boeckel GR, Tepasse PR, Reitnauer L, Koch R, Hasenkamp J, Bacher U, Scheithauer S, Trümper L, Schmitz N, Wulf G, Kerkhoff A, Lenz G, Krekeler C, Bleckmann A. Shumilov E, et al. Among authors: tepasse pr. Cancers (Basel). 2022 Jul 31;14(15):3746. doi: 10.3390/cancers14153746. Cancers (Basel). 2022. PMID: 35954410 Free PMC article.
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario.
Krekeler C, Reitnauer L, Bacher U, Khandanpour C, Steger L, Boeckel GR, Klosner J, Tepasse PR, Kemper M, Hennies MT, Mesters R, Stelljes M, Schmitz N, Kerkhoff A, Schliemann C, Mikesch JH, Schmidt N, Lenz G, Bleckmann A, Shumilov E. Krekeler C, et al. Among authors: tepasse pr. Cancers (Basel). 2022 Nov 9;14(22):5512. doi: 10.3390/cancers14225512. Cancers (Basel). 2022. PMID: 36428605 Free PMC article.
51 results